We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gene Mutation Increases Risk of Neurodevelopmental Disorders

By LabMedica International staff writers
Posted on 12 Sep 2017
Researchers have found that a rare variant of the G protein-coupled receptor CX3CR1, due to only a single amino acid substitution, may become useful in predicting increased risk for developing schizophrenia and autism.

Huntington's disease, cystic fibrosis, and muscular dystrophy are diseases that can be traced to a single mutation. More...
Diagnosis in asymptomatic patient for these diseases is relatively easy: you have the mutation? Then you are at risk. Complex diseases, on the other hand, do not have a clear mutational footprint. The new study, led by researchers at Nagoya University (Nagoya, Japan) and Osaka University (Osaka, Japan), have found a rare mutation that could act as a predictor for schizophrenia and autism.

"Aberrant synapse formation is important in the pathogenesis of schizophrenia and autism," said paper co-author Toshihide Yamashita, professor at Osaka University, "Microglia contribute to the structure and function of synapse connectivities." Microglia are the only cells in the brain that express the receptor CX3CR1. Mutations in this receptor are known to affect synapse connectivity and cause abnormal social behavior in mice. They have also been associated with neuroinflammatory diseases such as multiple sclerosis, but no study has shown a role in neurodevelopment disorders.

Working with this hypothesis, the researchers conducted a statistical analysis of the CX3CR1 gene in over 7000 schizophrenia and autism patients and healthy subjects, finding that one mutant candidate, a single amino acid switch from alanine to threonine, is a rare variant and a candidate marker for prediction. “Rare variants alter gene function but occur at low frequency in a population. They are of high interest for the study of complex diseases that have no clear mutational cause,” said Prof. Yamashita.

The structure of CX3CR1 includes a Helix-8 domain that is important for initiating a signaling cascade. Computer models showed that one amino acid change is enough to compromise the signaling. "The variant changes the region from hydrophobic to hydrophilic and destabilizes Helix 8. We overexpressed the mutation in cells and found Akt signaling was disrupted," explained Prof. Yamashita, adding that the findings are the first to connect a genetic variation in microglia with neurodevelopment disorders.

He hopes the discovery could become a basis for predictive diagnostics: "There is no reliable way to diagnose schizophrenia or autism in asymptomatic patients. Deeper understanding of the genetic risk factors will help us develop preventative measures," said Prof. Yamashita.

The study, by Ishizuka K et al, was published August 1, 2017, in the journal Translational Psychiatry.

Related Links:
Nagoya University
Osaka University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.